Setup

Natera (NTRA) is a $28B molecular diagnostics company with three product franchises: women's health (Panorama NIPT), oncology MRD (Signatera), and organ health (Prospera). Q1 2026 earnings (2026-05-07) delivered a beat-and-raise but the stock is down 11% on the week and 9% on the month, just broken below both its 50d ($201) and 200d ($199) moving averages. The pullback collides with three independent unpriced catalysts loading inside the next six months — and the cleanest of them is genuinely not in sell-side models.

What the call said

Revenue $697M (+39% YoY) on the first-ever million-unit quarter. Gross margin printed "just under 65%," but CFO Brophy and CEO Chapman both quantified a ≈1.5-2pp work-in-process headwind: an end-of-quarter volume surge dropped the receive-to-report ratio to 92% versus a normal 95-96%. COGS hit P&L as materials and labor consumed; revenue waited on Q2 reporting. Underlying Q1 unit economics ≈67%, which is above the FY26 guide they just raised to a 65% midpoint. The reversal is mechanical, not narrative.

Three forward catalysts management put on record:

Japan PMDA approval "on track for Q2 2026." Could land any week. Management framed Japan as potentially "effectively doubling" Signatera CRC volume TAM. 150+ Japanese institutions already experienced via the CIRCULATE-Japan study. Single national payer — one decision, national coverage.

ALPHA3 trial interim (large B-cell lymphoma, MRD-directed): 58% versus 17% MRD clearance in treatment versus observation, a 41 percentage point delta. ctDNA -98% in the treatment arm. This validates the December 2025 $424.5M Foresight Diagnostics acquisition on first clinical proof. Management disclosed "at least one more major pharma-sponsored trial contracted [using phased-variant technology] that we haven't yet announced."

Signatera ASP at $1,250, exit-2026 guide $1,275, long-term target $2,000. Seven MolDX histology submissions are in process — management explicitly stated these are NOT in guide. At current volumes, getting to $2,000 ASP would be ≈$750M of incremental gross profit.

What the market thinks

Mean analyst target $260 (+33% at time of writing); 17 of 19 ratings are Buy/Outperform/Overweight, with JPM, Evercore, and BTIG raising targets post-print to $250-$270. ATM IV on the 63-day expiry (which captures the Japan window) is 50% — squarely within the 52-week range, not pricing a binary catalyst. If options were pricing PMDA approval as a 70% binary, IV would sit at 70%+ and call skew would be more extreme. Option positioning is bullish (P/C open interest 0.24) but not catalyst-specific. Insiders sold $3.4M into the May pullback, but the pattern is RSU-vest-and-sell mechanical (Rabinowitz received a grant the same day he sold) at prices 22% below the February cluster — not the pattern an informed exit would produce.

Why the gap exists

The Japan catalyst is genuinely orphaned. A cross-corpus search across 10,607 earnings transcripts surfaced exactly zero other US oncology diagnostics with an active PMDA pathway. Sell-side has no comp to anchor a model on, so it gets left out of estimates entirely. The WIP-margin decode requires reading the call attentively for two minutes — sub-2pp gaps between reported and underlying are easy to miss in earnings-day noise. Cross-ticker corroboration confirms the heme MRD market is in expansion mode: ADPT's clonoSEQ DLBCL volume grew +19% QoQ post-Foresight close, with CMO Susan Bobulsky stating growth held "prior to and since the entry of competition." Both incumbents and entrants can grow simultaneously, which means the Foresight thesis doesn't depend on share rotation.

Risks (ranked)

1. Litigation overhang ≈$349M. Guardant Health $292.5M jury verdict plus Ravgen $57M, both pending appeal. Cash position $1.1B. Zero Q1 call commentary on appeal status, which is itself notable. Adverse 9th Circuit ruling could force material cash payment and reset the bear floor.

2. Japan PMDA slippage. Management's "on track Q2" is the modal path. If approval pushes to Q3-Q4, the unpriced asymmetry erodes and the position requires patience capital.

3. ALPHA3 final readout disappointment. Interim is interim. Final could narrow the delta or surface unfavorable subgroups. PhasED-Seq commercial launch ("later this year") slips if the clinical signal weakens.

4. Insider selling continuation. Mechanical 10b5-1 patterns can mask informed exits over multiple quarters. The bear lens stays open until a C-suite P-code (open market) purchase appears.

Catalysts

• Japan PMDA approval — Q2 2026, deadline 2026-09-30 (70%)
• NTRA Q2 2026 earnings — ≈2026-08-06; WIP reversal visible (70% on GM ≥66%)
• ADPT Q2 2026 earnings — ~early August; heme MRD market-structure indicator (62% on DLBCL ≥10% QoQ)
• Phased-variant clinical Signatera commercial launch — H2 2026, no specific date
• FIND-ECD enrollment complete — Q3 2026 (72%)
• Guardant 9th Circuit appeal ruling — no schedule disclosed

What would change our mind

• Japan PMDA receives a CRL or formal request for additional data
• ALPHA3 final readout shows <25 percentage point MRD-clearance delta
• ADPT Q2 2026 DLBCL sequential growth decelerates to <5% (signals share rotation, contradicts market-expansion thesis)
• Litigation appeal ruling adverse with material reserve increase
• Q2 reported GM <66% (falsifies WIP-reversal thesis)
• Conversely: any C-suite P-code purchase at sub-$200 prices flips the insider lens bullishly

Evidence